Shuttle Pharmaceuticals Holdings, Inc. reported second-quarter 2026 results reflecting a continuing transition of the business, with revenue of $0 and a net loss of $(3.15M), or diluted loss per share of $(3.10), compared with a net loss of $(3.71M) and diluted loss per share of $(32.91) in the year-ago quarter.

Financial Highlights

• Revenue: $0 for Q2 2026, unchanged from $0 in the year-ago quarter.
• Net income: Net loss of $(3.15M) for Q2 2026, improved from a net loss of $(3.71M) in the year-ago quarter.
• Diluted earnings per share: $(3.10) for Q2 2026, versus $(32.91) in the year-ago quarter.

Business Highlights

• Acquisition of Molecule.ai assets to integrate an AI-driven molecular discovery platform and accelerate early-stage drug R&D.
• Completed merger with United Dogecoin, making it a subsidiary focused on building energy-first digital infrastructure for mining, AI and HPC workloads.
• Strategic pivot from clinical development to AI and digital infrastructure: wound down Ropidoxuridine trials and reallocated resources toward AI and infrastructure initiatives.
• Raised capital through a public offering and PIPE to fund marketing, AI development, and expansion of digital infrastructure via United Dogecoin.
• Initial investments in technology deployment: purchased mining rigs, initiated co-location activities, and began development and amortization of the Molecule.ai platform.

Original SEC Filing: Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ] - 10-Q - Sep. 24, 2026